Program
Insulin Aspart
Also written as “insulin aspart”, “biphasic insulin aspart” and “Faster-acting insulin aspart”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Diabetes, Gestational, led by 9 companies.
Drug pageInsulin Aspart: every studyMany companies study it; this page follows only the 139 they lead. All 207 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 1280 open or running | phase 4since Nov 4, 2004 | Jul 17, 2003 | none ahead |
| Amphastar Pharmaceuticalsits history only | 20 open or running | phase 3since Sep 12, 2022 | Sep 12, 2022 | none ahead |
| Geropharmits history only | 20 open or running | phase 3since Sep 3, 2019 | Sep 3, 2019 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 1since Aug 8, 2007 | Aug 8, 2007 | none ahead |
| CeQurits history only | 10 open or running | no phasesince Mar 24, 2015 | Mar 24, 2015 | none ahead |
| Defymedits history only | 11 open or running | no phasesince Dec 3, 2021 | Dec 3, 2021 | Dec 2026NCT05221359 |
| Sunshine Lake Pharmaits history only | 10 open or running | phase 3since Mar 6, 2023 | Mar 6, 2023 | none ahead |
| The United Laboratories Internationalits history only | 10 open or running | no phasesince May 6, 2026 | May 6, 2026 | none ahead |
| Tonghua Dongbao Pharmaceuticalits history only | 10 open or running | phase 3since Jun 5, 2015 | Jun 5, 2015 | none ahead |
Also a collaborator on its studies: Mylan and Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 25, 2011.
- Jul 4, 2016Phase 3 study in Diabetes MellitusNovo Nordisk · NCT02825251 · 472 enrolled · United States, Belgium, Canada and more
- Jul 22, 2016Phase 1 study in HealthyNovo Nordisk · NCT02844790 · 24 enrolled · China
- Sep 15, 2016Phase 3 study in Diabetes MellitusNovo Nordisk · NCT02906917 · 532 enrolled · United States, Algeria, Czechia and more
- Oct 13, 2016Phase 1 study in Diabetes MellitusNovo Nordisk · NCT02933853 · 61 enrolled · Austria
- Jun 29, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03215498 · 58 enrolled · Germany
- Jan 5, 2018Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03407599 · 46 enrolled · Germany
- Jan 23, 2019Phase 2 study in Diabetes Mellitus, Type 1Novo Nordisk · NCT03816761 · 24 enrolled · United States
- Sep 3, 2019Geropharm’s first study: phase 3 study in Diabetes MellitusNew to GeropharmGeropharm · NCT04079413 · 264 enrolled · Russian Federation
- Nov 29, 2019No phase study in Clamp StudyGeropharm · NCT04184466 · 26 enrolled · Russian Federation
- Dec 3, 2021Defymed’s first study: no phase study in Diabetes Mellitus, Type 1New to DefymedDefymed · NCT05221359 · 8 planned · France
- Sep 12, 2022Amphastar Pharmaceuticals’ first study: phase 3 study in PharmacokineticsNew to Amphastar PharmaceuticalsAmphastar Pharmaceuticals · NCT05539872 · 69 enrolled · United States
- Mar 6, 2023Sunshine Lake Pharma’s first study: phase 3 study in Diabetes MellitusNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05802862 · 414 enrolled · China
- Apr 24, 2026Phase 3 study in PharmacokineticsAmphastar Pharmaceuticals · NCT07560150 · 62 enrolled · United States
- May 6, 2026The United Laboratories International’s first study: no phase study in Pharmacokinetics and PharmacodynamicsNew to The United Laboratories InternationalThe United Laboratories International · NCT07600944 · 44 enrolled · China
Ahead
- Dec 2026Primary completion: no phase study in Diabetes Mellitus, Type 1Defymed · NCT05221359
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 139 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07600944Pharmacokinetics and Pharmacodynamics · China | – | Completed | The United Laboratories International | Jun 13, 2026 | 44 |
| NCT07560150Pharmacokinetics · United States | 3 | Completed | Amphastar Pharmaceuticals | Jun 22, 2026 | 62 |
| NCT05802862Diabetes Mellitus · China | 3 | Completed | Sunshine Lake Pharma | Aug 16, 2024 | 414 |
| NCT05539872Pharmacokinetics · United States | 3 | Completed | Amphastar Pharmaceuticals | Jan 29, 2023 | 69 |
| NCT05221359Diabetes Mellitus, Type 1 · France | – | Recruiting | Defymed | Dec 2026 | 8 |
| NCT04184466Clamp Study · Russian Federation | – | Completed | Geropharm | Dec 19, 2018 | 26 |
| NCT04079413Diabetes Mellitus · Russian Federation | 3 | Completed | Geropharm | Jan 21, 2020 | 264 |
| NCT03816761Diabetes Mellitus, Type 1 · United States | 2 | Completed | Novo Nordisk | May 31, 2019 | 24 |
| NCT03407599Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 5, 2018 | 46 |
| NCT03215498Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 20, 2017 | 58 |
| NCT02933853Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Dec 21, 2017 | 61 |
| NCT02906917Diabetes Mellitus · United States, Algeria, Czechia and more | 3 | Completed | Novo Nordisk | Aug 31, 2017 | 532 |
| NCT02844790Healthy · China | 1 | Completed | Novo Nordisk | Sep 26, 2016 | 24 |
| NCT02825251Diabetes Mellitus · United States, Belgium, Canada and more | 3 | Completed | Novo Nordisk | Jun 20, 2017 | 472 |
| NCT02762578Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | May 19, 2017 | 543 |
| NCT02670915Diabetes Mellitus · United States, Bulgaria, Czechia and more | 3 | Completed | Novo Nordisk | Feb 5, 2018 | 834 |
| NCT02648217Diabetes Mellitus · Algeria, India, Lebanon and more | 3 | Completed | Novo Nordisk | Sep 4, 2016 | 263 |
| NCT02594033Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jan 28, 2016 | 46 |
| NCT02568280Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Apr 25, 2016 | 42 |
| NCT02500706Diabetes Mellitus · United States, Austria, Bulgaria and more | 3 | Completed | Novo Nordisk | Jul 17, 2017 | 1,108 |
| NCT02491528Diabetes Mellitus · China | 3 | Completed | Tonghua Dongbao Pharmaceutical | Aug 12, 2016 | 563 |
| NCT02419859Diabetes Mellitus, Type 2 · Austria | – | Completed | CeQur | Nov 2015 | 20 |
| NCT02131246Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Jul 2014 | 33 |
| NCT02089451Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 6, 2014 | 21 |
| NCT02035371Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 24, 2014 | 41 |
| NCT02033239Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2014 | 46 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 11, 2016 | 501 |
| NCT02003677Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 14, 2014 | 67 |
| NCT01999322Diabetes Mellitus · United States, Germany | 3 | Completed | Novo Nordisk | May 14, 2014 | 37 |
| NCT01992588Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2014 | 48 |
| NCT01934712Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Jan 28, 2014 | 50 |
| NCT01924637Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Nov 2013 | 36 |
| NCT01892020Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | May 2014 | 161 |
| NCT01868568Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2008 | 55 |
| NCT01868555Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Feb 2008 | 32 |
| NCT01865331Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2007 | 32 |
| NCT01865305Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Feb 2007 | 59 |
| NCT01835431Diabetes Mellitus · United States, Belgium, Brazil and more | 3 | Completed | Novo Nordisk | Nov 7, 2014 | 362 |
| NCT01814137Diabetes Mellitus · United States, Algeria, Germany and more | 3 | Completed | Novo Nordisk | Mar 2014 | 40 |
| NCT01773798Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Aug 2013 | 33 |
| NCT01713530Diabetes Mellitus · United States, Algeria, Austria and more | 3 | Completed | Novo Nordisk | Jan 9, 2014 | 274 |
| NCT01707134Diabetes Mellitus · Austria, Denmark, Finland and more | 3 | Completed | Novo Nordisk | May 2000 | 753 |
| NCT01704378Diabetes Mellitus · Finland, Norway, Sweden and more | 4 | Completed | Novo Nordisk | Mar 14, 2003 | 89 |
| NCT01698697Diabetes Mellitus · South Africa | 1 | Completed | Novo Nordisk | Oct 18, 2002 | 24 |
| NCT01682902Diabetes Mellitus · United States | 1 | Completed | Novo Nordisk | Mar 2013 | 43 |
| NCT01650129Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Oct 18, 2001 | 83 |
| NCT01620437Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Dec 30, 2003 | 30 |
| NCT01620333Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Apr 2000 | 24 |
| NCT01618188Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Sep 7, 2012 | 52 |
| NCT01538511Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 13, 2007 | 59 |
| NCT01536028Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2006 | 32 |
| NCT01530048Diabetes Mellitus · Denmark | 1 | Completed | Novo Nordisk | May 2006 | 34 |
| NCT01527656Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Feb 2004 | 40 |
| NCT01527643Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Dec 17, 2003 | 30 |
| NCT01527630Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Jan 8, 2003 | 30 |
| NCT01527565Diabetes Mellitus · South Africa | 1 | Completed | Novo Nordisk | Feb 26, 2003 | 30 |
| NCT01527552Diabetes Mellitus · South Africa | 1 | Completed | Novo Nordisk | Dec 18, 2002 | 30 |
| NCT01526980Diabetes Mellitus · United Kingdom | 2 | Completed | Novo Nordisk | Nov 2002 | 31 |
| NCT01526941Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2001 | 27 |
| NCT01649570Diabetes Mellitus · Japan | 4 | Completed | Novo Nordisk | Aug 2003 | 123 |
How it is read
Names in the registry
- “insulin aspart”, 60 entries
- “biphasic insulin aspart”, 27 entries
- “Faster-acting insulin aspart”, 24 entries
- “biphasic insulin aspart 50”, 13 entries
- “biphasic insulin aspart 70”, 12 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 57 studies
- Diabetes Mellitus, Type 1, 54 studies
- Diabetes Mellitus, 28 studies
- Diabetes, Gestational, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.